Evidence map›Paper›PMID 42758191›Full record

ArticleSurgery today2026

Recurrence-free survival in patients with stage III colorectal cancer who did or did not complete adjuvant chemotherapy.

Shintaro Hashimoto, Toshio Shiraishi, Tetsuro Tominaga, Keisuke Noda, Mariko Yamashita, Hiroki Katayama, Hiroshi Maruta, Yuma Takamura, Hideaki Komatsu, Kenji Tanaka and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shintaro HashimotoDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID http://orcid.org/0000-0002-1849-8754
Toshio ShiraishiDepartment of Surgery, Saiseikai Nagasaki Hospital, Nagasaki, Japan.
Tetsuro TominagaDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Keisuke NodaDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Mariko YamashitaDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroki KatayamaDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroshi MarutaDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yuma TakamuraDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hideaki KomatsuDepartment of Surgery, Saiseikai Nagasaki Hospital, Nagasaki, Japan.
Kenji TanakaDepartment of Surgery, Saiseikai Nagasaki Hospital, Nagasaki, Japan.
Takashi NonakaDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. tnonaka@nagasaki-u.ac.jp.
Keitaro MatsumotoDivision of Thoracic and Pelvic Surgery, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the impact of adjuvant chemotherapy continuity on the recurrence-free survival in real-world patients with stage III colorectal cancer.

methodsWe retrospectively analyzed 281 patients with pathologic stage III colorectal cancer who underwent curative resection at two institutions in Japan. Patients were classified into three groups according to their adjuvant chemotherapy status: completion, discontinuation, or no initiation. Recurrence-free survival was compared between the groups. Factors associated with treatment discontinuation were assessed using a multivariable logistic regression analysis.

resultsAmong the 159 patients who initiated adjuvant chemotherapy, 116 (73.0%) completed the planned course. Completion was associated with a significantly better recurrence-free survival than discontinuation (5-year recurrence-free survival 77.6% vs. 56.5%, p=0.013). Recurrence-free survival in the discontinuation group was similar to that in patients without chemotherapy (56.5% vs. 55.8%, p=0.498). Severe adverse events (CTCAE grade 3 or higher) were independently associated with treatment discontinuation (odds ratio 6.658, 95% confidence interval 2.807-16.740, p<0.001). Most discontinuations occurred within the first three months (78.9%). In patients who initiated chemotherapy, discontinuation was independently associated with a poorer recurrence-free survival (RFS).

conclusionsCompletion of adjuvant chemotherapy was associated with an improved recurrence-free survival, whereas early discontinuation, largely driven by severe toxicity, was associated with inferior survival outcomes.

Indexed as

Adjuvant chemotherapyColorectal cancerRecurrence-free survivalTreatment discontinuation

Identifiers

PMID42758191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.